Articles > Health magazines > Medical magazines > Obesity & Diabetes Week articles > March 2003

Article: New antiobesity agents promote weight loss in type 2 diabetic patients.

Article from:
Obesity & Diabetes Week
Article date:
March 17, 2003
Copyright

2003 MAR 17 - (NewsRx.com & NewsRx.net) -- New antiobesity agents, sibutramine and orlistat, promote weight loss in obese patients with type 2 diabetes.

"Besides genetic predisposition, obesity is the most important risk factor for the development of type 2 diabetes mellitus. Even modest weight reduction can improve blood glucose control in overweight subjects. After failure of lifestyle modifications, antiobesity drugs such as orlistat, a potent and selective inhibitor of gastric and pancreatic lipases that reduces lipid intestinal absorption, or sibutramine, a noradrenaline and 5-hydroxytryptamine reuptake inhibitor that regulates food intake, may be ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: New antiobesity agents promote weight ...
Obesity, Fitness & Wellness Week;  March 22, 2003 ;     688 words ... ... net) -- New antiobesity agents, sibutramine ... orlistat, promote weight loss in obese patients ... able to promote weight loss in obese type ... reduced after weight loss." The researchers ... concluded, "These antiobesity agents may also contribute ...

Antiobesity agents.(SECTION 14: NUTRITION)
MPR Monthly Prescribing Reference;  November 1, 2005 ;     700+ words ...Sympathomimetic. Phentermine HCI 37.5mg; caps: scored tabs. Indications: Short-term monotherapy as adjunct n management of exogenous obesity in patients with initial body mass 30kg/m2, or [greater than or equal to] 27kg/[m.sup.2] in presence of | other risk factors. Adults: [grater than or equal

14E Antiobesity agents.(SECTION 14: NUTRITION)(exogenous ...
Physician Assistants' Prescribing Reference;  December 22, 2005 ;     700+ words ...ADIPEX-P Gate CIV Sympathomimetic. Phentermine HCl 37.5mg; caps; scored tabs. Indications: Short-term monotherapy as adjunct in management of exogenous obesity in patients with initial body mass [greater than or equal to] 30kg/[m.sup.2], or [greater than or equal to] 27kg/[m.sup.2] in presence of

14E antiobesity agents.(Drug overview)
Nurse Practitioners' Prescribing Reference;  March 22, 2006 ;     700+ words ...ADIPEX-P Gate CIV Sympathomimetic. Phentermine HCI 37.5mg; caps; scored tabs. Indications: Short-term monotherapy as adjunct in management of exogenous obesity in patients with initial body mass [greater than or equal to]30kg/[m.sup.2], or [greater than or equal to]27kg/[m.sup.2] in presence of

14E Antiobesity agents.(SECTION 14: NUTRITION)
MPR Monthly Prescribing Reference;  February 1, 2006 ;     700+ words ...ADIPEX-P Gate CIV Sympathomimetic. Phentermine HCl 37.5mg; caps; scored tabs. Indications: Short-term monotherapy as adjunct in management of exogenous obesity in patients with initial body mass [is greater than or equal to] 30kg/[m.sup.2], or [greater than or equal to] 27kg/[m.sup.2] in presence

14E antiobesity agents.(SECTION 14: NUTRITION)(Drug ...
Physician Assistants' Prescribing Reference;  March 22, 2006 ;     700+ words ...ADIPEX-P Gate CIV Sympathomimetic. Phentermine HCl 37.5mg; caps; scored tabs. Indications: Short-term monotherapy as adjunct in management of exogenous obesity in patients with initial body mass [greater than or equal to] 30kg/[m.sup.2], or [greater than or equal to] 27kg/[m.sup.2] in presence of

14E Obesity.(use of antiobesity agents)
MPR Monthly Prescribing Reference;  November 1, 2006 ;     700+ words ...ADIPEX-P Gate CIV Sympathomimetic. Phentermine HCI 37.5mg; caps; scored tabs. Indications: Short-term monotherapy as adjunct in management of exogenous obesity in patients with initial body mass [greater than or equal to] 30kg/[m.sup.2], or [greater than or equal to] 27kg/[m.sup.2] in presence of

14E Obesity.(SECTION 14: NUTRITION)(treating with antiobesity ...
MPR Monthly Prescribing Reference;  January 1, 2007 ;     700+ words ...ADIPEX-P Gate CIV Sympathomimetic. Phentermine HCl 37.5mg; caps; scored tabs. Indications: Short-term monotherapy as adjunct in management of exogenous obesity in patients with initial body mass [greater than or equal to] 30kg/[m.sup.2], or [greater than or equal to] 27kg/[m.sup.2] in presence of

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives